TISLELIZUMAB-JSGR

224 reported adverse events

Drug classes: Programmed Death Receptor-1 Blocking Antibody [EPC]

These side effects are most commonly reported by patients taking TISLELIZUMAB-JSGR:

# Side effect Count
0 DISEASE PROGRESSION 80
1 OFF LABEL USE 26
2 MALIGNANT NEOPLASM PROGRESSION 25
3 ANAEMIA 21
4 THROMBOCYTOPENIA 21
5 LYMPHADENOPATHY 19
6 PNEUMONIA 12
7 DECREASED APPETITE 10
8 RICHTER^S SYNDROME 10
9 DEATH 9
See all common reactions for TISLELIZUMAB-JSGR

TISLELIZUMAB-JSGR is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 OESOPHAGEAL WALL HYPERTROPHY 1 0.0294
1 PULMONARY TUMOUR THROMBOTIC MICROANGIOPATHY 1 0.0130
2 TUMOUR PERFORATION 4 0.0126
3 VASCULITIS GASTROINTESTINAL 1 0.0090
4 TRACHEAL FISTULA 1 0.0065
5 MYOCARDITIS-MYOSITIS-MYASTHENIA GRAVIS OVERLAP SYNDROME 1 0.0044
6 METASTASES TO CHEST WALL 1 0.0029
7 CYTOMEGALOVIRUS ENTERITIS 1 0.0028
8 PORTAL VENOUS GAS 1 0.0028
9 MOUTH BREATHING 1 0.0023
See all enriched reactions for TISLELIZUMAB-JSGR